Skip to content
Manufacturing Today

AbbVie opens 12,000 sq ft Oxford R&D site as UK commitments top £120m

AbbVie opens 12,000 sq ft Oxford R&D site as UK commitments top £120m
AbbVie has expanded its UK research and development operations with a new 12,000 sq ft facility in Oxford. The site, known as AbbVie Oxford, forms part of more than £120m the company has invested and committed to scientific research, academic collaborations and talent development across the UK.
The facility will strengthen research in immunology, neuroscience and oncology, combining specialist biotechnology expertise with the resources of AbbVie's global R&D network.

Built on the DJS Antibodies acquisition

The expansion builds on AbbVie's 2022 purchase of Oxford-founded biotech DJS Antibodies for about $255m. That deal brought antibody discovery capabilities and an existing research team into the group.
DJS Antibodies was established in 2014 and developed antibody medicines aimed at difficult-to-drug proteins. Its lead programme, DJS-002, targeted the lysophosphatidic acid receptor 1 (LPAR1) for potential use in idiopathic pulmonary fibrosis and other fibrotic diseases.

UK footprint and pipeline

AbbVie employs more than 1,100 people in the UK across Oxford, Maidenhead and Marlow, and works with more than 100 universities and research organisations each year. Existing partnerships include research with the University of Oxford into how patients with inflammatory conditions respond to different treatments at molecular and clinical levels. The company also funds a postdoctoral programme examining the biological drivers of inflammatory diseases.
Its latest reported pipeline contains around 90 compounds, devices and indications, with about 60 programmes in mid- and late-stage development. These include investigational treatments for inflammatory and autoimmune conditions, neurological disorders and several cancers. AbbVie invested $13.8bn in global R&D last year.

Wider pharma investment

According to the Association of the British Pharmaceutical Industry, the sector attracted an additional £2bn in investment commitments between September 2025 and September 2026, covering drug discovery, clinical research and medicines manufacturing. Other major commitments include UCB's £500m R&D and early manufacturing hub in Windlesham, Surrey, and AstraZeneca's £300m backing for its UK operations.
AbbVie said the Oxford expansion would help strengthen collaboration across the UK life sciences ecosystem, bringing together academic expertise, clinical research and scientific talent to advance potential new treatments.

Source: Manufacturing Chemist · Image: Pixabay

Related stories